<DOC>
	<DOC>NCT00952887</DOC>
	<brief_summary>The purpose of this study is to establish safe dose levels of ACE-031 in healthy postmenopausal women following multiple dose administration. This study will also evaluate if ACE-031 has an effect on muscle.</brief_summary>
	<brief_title>A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<criteria>Postmenopausal Body mass index (BMI) of ≥ 18.5 to &lt; 32. History of malignancy, except excised or treated basal cell carcinoma, cervical carcinoma insitu, or ≤ 2 squamous cell carcinomas History of clinically significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease. History of opportunistic infection (e.g. invasive candidiasis or pneumocystis pneumonia) within 6 months prior to screening or serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g., septicemia) within 3 months prior to screening. Surgery within 3 months prior to Day 1 (other than minor cosmetic or dental procedures). Fever or symptomatic viral or bacterial infection within 7 days prior to Day 1. Donation or significant loss of blood within 2 months prior to Day 1. Hormone replacement therapy within 3 months prior to Day 1. Treatment with erythropoiesis stimulating agents (Epogen, Procrit, Aranesp, etc) within 2 months prior to Day 1. Systemic glucocorticoid therapy within 6 months prior to Day 1. Treatment with another investigational drug or approved therapy for investigational use within 1 month prior to Day 1. Previous treatment with ACE031.</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>